GlassScriptPhysician profile
Craig James Mcclain
NPI 1225092349
$21,558.40
in general payments reported to CMS, 2019-2025
12 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $1,965 · 2021: $2,561 · 2023: $426 · 2024: $2,939 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $2,713 · Food and Beverage: $1,519 · Travel and Lodging: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,127.38 |
| Consulting Fee | $2,712.50 |
| Food and Beverage | $1,518.89 |
| Travel and Lodging | $1,262.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15,411.67 | 2023-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $4,407.77 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $499.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $444.65 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $274.85 | 2019 | |
| Perspectum Diagnostics LTD | $148.36 | 2023 | Livermultiscan |
| Nestle Healthcare Nutrition INC. | $126.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.43 | 2024 | |
| Albireo Pharma, INC. | $53.83 | 2024 | Iqirvo, Bylvay |
| Ipsen Biopharmaceuticals, INC | $52.21 | 2025 | Iqirvo |
| Conmed Corporation | $36.26 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.